MAP2K1 and neoplasm: A pre-clinical study supporting the above results was done by Pitt et al. where they demonstrated suppression of tumor progression in CRC cell lines and tumor xenografts models with combinatory PI3K/mTOR inhibitor PF-502 and the MEK1/2 inhibitor PD-901 [79].